October 20, 2026 10:19 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
‘Operation completed’: Tiger Shroff shooters allegedly alerted handlers after firing, probe reveals | 'I don't mind saying sorry 1,000 times': Sonu Nigam apologises to Kannadigas over ‘Pahalgam’ remark amid concert ban demand | After Vijay, is Dhanush eyeing politics? TVK calls Thalapathy an inspiration | Trump Says Paris Will Become ‘Muslim City Very Soon’, Blames Macron’s Immigration Policies | Four killed in fresh Manipur violence as protesters take bodies to Chief Minister’s residence | Tiger Shroff firing: Three accused arrested on train in Rajasthan, suspected Bishnoi gang link emerges | 'Internet access a fundamental right for children': SC rejects age-based 'blanket' ban | 'We will fight our own government': RG Kar victim's father threatens fresh protest after Sandip Ghosh gets bail | RG Kar shocker: Sandip Ghosh gets bail as only 7 of 147 witnesses examined, junior doctor blasts CBI | Trump waives Russia-related sanctions

Aurobindo Pharma receives USFDA approval for drug related to moderate dementia

| | Mar 29, 2016, at 08:16 pm
Hyderabad/Mumbai, Mar 29 (IBNS) Aurobindo Pharma Limited, which manufactures generic pharmaceuticals and active pharmaceutical ingredients, announced on Tuesday that the company has received the final approval from the US Food & Drug Administration (USFDA) to manufacture and market Rivastigmine Tartrate Capsules USP, 1.5 mg, 3 mg, 4.5 mg and 6 mg.
This product is expected to be launched in the first quarter of fiscal year 2016-17.
 
The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Exelon Capsules, 1.5 mg, 3 mg, 4.5 mg and 6 mg, of Novartis Pharmaceuticals Corporation, said the company.
 
Naproxen Sodium Tablets is used in the treatment of mild moderate dementia of the Alzheimer's and Parkinson's disease. 
 
The approved product has an estimated market size of US$ 26.7 million for the twelve months ending January 2016 according to IMS.
 
This is the 67th ANDA (including 14 tentative approvals) to be approved out of Unit VII formulation facility in Hyderabad, India for manufacturing oral non-antibiotic products. 
 
Aurobindo now has a total of 246 ANDA approvals (211 Final approvals including 10 from Aurolife Pharma LLC and 35 tentative approvals) from USFDA.
#Aurobindo Pharma receives USFDA # US Food & Drug Administration

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.
Related Images
In Images: Gautam Adani offers prayers at Kalighat Temple in Kolkata
In Images: Gautam Adani offers prayers at Kalighat Temple in Kolkata Sep 24, 2026, at 11:48 am
In Images: Amit Shah performs 'Bhoomi Pujan' of Amul's curd manufacturing plant in Kolkata
In Images: Amit Shah performs 'Bhoomi Pujan' of Amul's curd manufacturing plant in Kolkata Jul 19, 2026, at 10:57 pm
Nirmala Sitharaman presents Budget 2025
Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:41 pm
Related Videos
RBI announces repo rate cut Jun 06, 2025, at 10:51 am
FM Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:45 pm
Nirmala Sitharaman on Budget 2024 Jul 23, 2024, at 09:30 pm